Post by
FactFinder1994 on Feb 27, 2023 9:29am
Med-Tech Stock Bridging the Multibillion $ Transplant Gap
“Integrating rapid diagnostics is a major step forward in lung transplantation. By providing transplant teams with quantitative metrics to more accurately assess donor lungs, we are moving decision making in transplantation into the era of personalized medicine.”
- Dr. Shaf Keshavjee, Surgeon-in-Chief, Sprott Department of Surgery, Director, Toronto Lung Transplant Program and Director, Latner Thoracic Surgery Research Laboratories.
The costs associated with anything in the medical field are high, this we know, but costs are always highest where there are unmet needs, and where this occurs, we find opportunity.
According to the Canadian Institute for Health Information, there are roughly 15,000 donor lungs available in North America yearly – but only about 3,000 (20%) are transplanted. For those that do receive a transplant, there is also the issue of debt, life at risk post-op, hospitalization is expensive, but a unique company in the med-tech space is out to fill this gap and help people breathe a little easier, perhaps it could spell good news for an investment portfolio.
SQI Diagnostics are leaders in the science of lung health. We develop and manufacture respiratory health and precision medicine tests that run on SQI’s fully automated systems. We’re driven to create and market life-saving testing technologies that help more people in more places live longer, healthier lives. The firm is focused on developing the business units targeting organ transplant, autoimmune disease, and serological testing.